EGFR Inhibitors in the Treatment of Lung Cancer

Publisher： Karger

E-ISSN： 2296-5262|30|10|476-476

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.10, 2007-09, pp. : 476-476

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 2, 2011-05 ,pp. : 228-233

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

By  

Oncology, Vol. 86, Iss. 2, 2014-01 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations

By  

Oncology Research and Treatment, Vol. 40, Iss. 1-2, 2017-01 ,pp. : 7-13

Karger

Access to resources Recommend Favorite

Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors

By  

Oncology, Vol. 87, Iss. 2, 2014-07 ,pp. : 83-94

Karger

Access to resources Recommend Favorite

Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer

By  

Current Signal Transduction Therapy, Vol. 3, Iss. 3, 2008-09 ,pp. : 234-243

Bentham Science Publishers

Access to resources Recommend Favorite